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Background: The aim of our study is to establish the potential role of dual-phase 18F-fluorodeoxyglucose positron
emission tomography / computed tomography (FDG-PET/CT) in patients presenting ovarian masses with diffuse
peritoneal infiltration for differentiating benign from malignant lesions.
Methods: Twenty patients (13 with ovarian cancers and 7 with benign lesions) were evaluated preoperatively by
dual-phase 18F-FDG-PET/CT performed 1 h and 2 h after injection of 18F-FDG. The maximum standardized uptake
value (SUVmax) for both time points SUVmax1 and SUVmax2 were determined, respectively, and the retention index
(RI) was calculated by subtracting the SUVmax1 from the SUVmax2 and dividing by SUVmax1.
Results: The areas under the receiver operating characteristic curves (AUCs) of SUVmax1 and SUVmax2 were 0.753
(P = 0.062, 95% confidence interval [CI] = 0.512–0.915) and 0.835 (P = 0.001, 95% CI = 0.604–0.961), respectively.
The AUC of the RI was 0.901 (P < 0.001, 95% CI = 0.684–0.988). Using pairwise comparisons, the AUC of SUVmax2
was significantly higher than that of SUVmax1 (P = 0.032). The AUC of the RI was higher than those of SUVmax1
and SUVmax2, but the difference was not statistically significant.
Conclusion: Dual-phase 18F-FDG PET/CT might be considered when preoperative imaging is indeterminate. A
larger-scaled, prospective study is needed to verify these results.
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Epithelial ovarian cancer is the leading cause of death
among all other gynecological malignancies. The symp-
toms of this cancer are usually nonspecific, and most
women are diagnosed at advanced stages. Therefore, early
detection and characterization is crucial in patients who
present with an adnexal mass for prompt surgical interven-
tion and for improving survival. However, characterization
of adnexal masses is often challenging to clinicians because
both benign and malignant adnexal masses have overlap-
ping imaging features [1]. To date, no strategies have
proved to be effective in screening and early diagnosis of
ovarian cancer [2]. Numerous imaging modalities, includ-
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unless otherwise stated.imaging (MRI), have been proposed as useful adjuncts to
conventional ultrasound for the detection of ovarian can-
cer. However, despite having higher sensitivity and specifi-
city than ultrasound, preoperative diagnosis using CT or
MRI is often indeterminate [3,4]. Until recently, most
series have used 18F-fluorodeoxyglucose-positron emission
tomography/CT (18F-FDG-PET/CT) to detect recurrence
or distant metastasis [5-8]. In contrast, only a few studies
have demonstrated the effectiveness of 18F-FDG-PET/CT
in detecting primary ovarian cancer [9,10]. Despite high
diagnostic value in identifying primary ovarian cancer,
some pitfalls exist. False-positive results have been reported
in patients with pelvic inflammatory disease (PID),
tubo-ovarian abscess, and endometriosis [11,12], and
false-negative results have been reported in patients
with borderline tumors and early stage ovarian cancer [13].
To overcome this problem, acquisition of delayed im-
ages has been suggested. A previous study has demonstrated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of patients
Characteristics Malignant (N = 13) Benign (N = 7)
Age (years) 64 (50–80) 48 (30–69)
Parity 2 (0–3) 2 (0–4)
BMI (kg/m2) 23.5 ± 4.6 25.8 ± 5.5
Histopathology 8 serous 3 pelvic tuberculosis
3 mucinous 3 endometriosis
2 endometrioid 1 PID
Tumor size (cm) 7.5 (4–20) 3 (1–7)
SUVmax1 7.7 (3.3-11.2) 3.2 (1.7-8.8)
SUVmax2 10.1 (4.3-16.8) 4.3 (2.3-10.2)
RI 40 (16.2-50.0) 15.9 (1.2-35.3)
BMI = body mass index, SUV = standardized uptake value, RI = retention index,
PID = pelvic inflammatory disease.
Data are presented as median (range) or mean ± SD.
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the injection of the radiotracer in various malignancies [14].
This dual-time acquisition procedure has proved to be valu-
able in differentiating benign from malignant lesions in
some solid tumors [15-19]. However, it has not been vali-
dated in patients with ovarian cancers.
The aim of our study is to establish the potential role
of dual-phase 18F-FDG PET/CT for improving diagnostic
accuracy of ovarian cancers.
Methods
Patients
From March 2009 to February 2011, we enrolled 20 con-
secutive patients presenting ovarian masses with diffuse
peritoneal infiltration identified on abdomen–pelvis CT
or pelvic MRI scans at Guro Hospital, Korea University.
Each patient underwent conventional diagnostic work-
up, including physical examination, pelvic ultrasound,
and abdomen–pelvis CT or pelvic MRI. In all patients,
images on CT or MRI suggested either benign or malig-
nant masses with similar probability, making differential
diagnosis difficult. To further confirm the characteristics
of the masses, dual-phase 18F-FDG-PET/CT examina-
tions were then performed in all patients. Patients who
were pregnant, had a history of other types of cancers,
or had liver cirrhosis, renal failure, or cardiovascular dis-
ease were excluded. All suspicious lesions were con-
firmed histopathologically by surgical exploration. The
study protocol was approved by the Institutional Review
Board for Research on Human Subjects at the Guro
Hospital, Korea University, and written informed con-
sent was obtained from all patients.
Dual-phase 18F-FDG-PET/CT examination
All patients fasted for at least 6 h to maintain serum glucose
level of <140 mg/dL before examination. One hour after
intravenous injection of 555 MBq of 18F-FDG, each patient
was scanned from the cerebellum to the pelvis using a PET/
CT scanner (Gemini Time of Flight PET/CT, Philips,
Amsterdam, the Netherlands). An additional delayed scan of
the same area was taken 2 h after the 18F-FDG injection
using the same scanner. Neither muscle relaxant nor con-
trast agent was administered.
18F-FDG-PET/CT data analysis
All images were interpreted and analyzed by 2 experi-
enced nuclear medicine physicians with all available
clinical information. PET images were analyzed on a
dedicated workstation (Extended Brilliance Workspace
3.5 with PET/CT viewer for automated image registra-
tion, Philips, Amsterdam, the Netherlands). After image
reconstruction, regions of interest were accurately placed
over the lesion visualized on the PET images. All regions
of interest were quantitatively evaluated using thestandardized uptake value (SUV). The maximum SUV
was calculated using the following formula:
SUV ¼ tissue concentration injected dose‐1  body weight‐1
For quantitative analysis of the uptake of the lesion, a re-
gion of interest was placed over the area of maximum ac-
tivity within the lesion, and the maximum SUV (SUVmax)
was calculated from the measured tissue concentration at
1 h (SUVmax1) and 2 h (SUVmax2). The retention index (RI)
was calculated by subtracting the SUVmax 1from the SUVmax
2and dividing by SUVmax 1.
Statistical analysis
The diagnostic accuracy of 18F-FDG-PET/CT in differ-
entiating benign from malignant lesions was determined
based on the histopathological findings. Numerical data
such as age, parity, and body mass index were expressed
as median (range). Mean percentage changes between
SUVmax1 and SUVmax2 in both malignant and benign le-
sions were calculated, and were compared using the
two-tailed Student’s t-test. Individual receiver-operating
characteristic (ROC) curves of SUVmax1, SUVmax2, and
RI were analyzed to determine their clinical signifi-
cance in differentiating benign from malignant lesions.
Pairwise comparisons of their performances were con-
ducted using the Hanley and McNeil method. A P value
of <0.05 was considered statistically significant. All statis-
tical analyses were conducted using MedCalc Software for
Windows (Version 11.6.0, MedCalc Software bvba,
Ostend, Belgium).
Results
Baseline characteristics of the enrolled patients are sum-
marized in Table 1. Of the 20 patients, 13 were histo-
pathologically diagnosed with primary epithelial ovarian
cancers; 8 serous, 3 mucinous, and 2 endometrioid. The
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tuberculosis (3 patients), endometriosis (3 patients), and
PID (1 patient). The median size of ovarian masses in 13
patients with primary epithelial ovarian cancers was
9.5 cm (range, 4–20), whereas the median size of ovarian
masses in 7 patients with non-cancerous lesions was
3 cm (range, 1–7). In addition, all 20 patients showed
diffuse peritoneal infiltration, such as peritoneal nodular-
ity, omental or mesenteric infiltration, suggesting peri-
toneal carcinomatosis. Preoperative findings on CT or
MRI scans in 13 patients with primary epithelial ovarian
cancers mostly suggested malignancy as the first differ-
ential diagnosis, but other conditions could not be ex-
cluded using these scans, such as borderline ovarian
malignancy, benign ovarian tumors, or soft tissue masses.
In contrast, CT or MRI findings in 7 patients with benign
lesions strongly suggested malignancies, but the possibil-
ities of benign inflammatory lesions could not be com-
pletely excluded.
The mean percentage changes between SUVmax1 and
SUVmax2 in malignant and benign lesions were 2.6 ± 1.4
and 0.6 ± 0.4, respectively, indicating that SUVmax was
significantly increased in malignant compared to benignFigure 1 The PET/CT images taken 1 h and 2 h after 18F-FDG injection
(a) and pelvic tuberculosis (b). (a) Whole body MIP image (upper). Axial
FDG uptake at 1 h (lower) (b) Whole body MIP image (upper). Axial image
(lower). MIP = multiple intensity projection.lesions (P = 0.014). The PET/CT images taken 1 and 2 h
after 18F-FDG injection in a patient with ovarian cancer
and peritoneal carcinomatosis and in a patient with pel-
vic tuberculosis are presented in Figure 1. SUVmax1 was
11.5 and 10.1 in a patient with ovarian cancer and a pa-
tient with pelvic tuberculosis, respectively. However,
SUVmax2 increased to 13.6 in the patient with ovarian
cancer, whereas it decreased to 10.0 in the patient with
pelvic tuberculosis. The results of the ROC analysis of
SUVmax1 are shown in Figure 2. The area under the
curve (AUC) of SUVmax1 was 0.753 (P = 0.063, 95% con-
fidence interval [CI] = 0.512–0.915), indicating that was
not a useful parameter in differentiating benign from
malignant lesions. When the SUVmax1 cutoff value was
set at 3.2, the sensitivity and specificity were 100% and
57.1%, respectively. The results of the ROC analysis of
SUVmax2 are shown in Figure 3. In contrast, the AUC of
SUVmax2 was 0.835 (P = 0.001, 95% CI = 0.604–0.961),
showing that the clinical usefulness of SUVmax2 in dif-
ferentiating benign from malignant lesions was statisti-
cally significant. When the SUVmax2 cutoff value was
set at 3.9, the sensitivity and specificity were 100% and
57.1%, respectively. Figure 4 shows the results of thein a patient with ovarian cancer with peritoneal carcinomatosis
image showed that FDG uptake at 2 h was significantly increased than
showed almost no change of FDG uptake between at 2 h and at 1 h
Figure 2 Receiver operating curve analysis of standardized
uptake value (SUV)max1. The sensitivity and specificity were
calculated when the SUVmax1 cutoff value was set at 3.2.
Figure 4 Receiver operating curve analysis of retention index.
The sensitivity and specificity were calculated when the retention
index cutoff value was set at 16.67.
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95% CI = 0.684–0.988), showing the greatest signifi-
cance among the 3 parameters (SUVmax1, SUVmax2,
and RI). When the RI cutoff value was set at 16.67,
the sensitivity and specificity were 92.3% and 71.4%,
respectively.
Pairwise comparison of the ROC curves was per-
formed to compare the clinical utility of the 3 parame-
ters in differentiating benign from malignant lesions.
The AUC of SUVmax2 was significantly higher than that
of SUVmax1 (P = 0.032). The AUC of RI was higher than
both those of SUVmax1 and SUVmax2, but the differences
obtained were not statistically significant.Figure 3 Receiver operating curve analysis of standardized
uptake value (SUV)max2. The sensitivity and specificity were
calculated when the SUVmax2 cutoff value was set at 3.9.Discussion
The purpose of this study was to evaluate the value of
dual-phase 18F-FDG-PET/CT in differentiating benign
from malignant lesions in patients with indeterminate
adnexal masses. We demonstrated that SUVmax2 mea-
sured from images obtained from delayed phase scan-
ning have a pivotal role when preoperative diagnosis is
indeterminate. To the best of our knowledge, this is the
first study to evaluate the clinical effectiveness of dual-
phase 18F-FDG-PET/CT in the initial diagnosis of sus-
pected malignant adnexal masses.
Although 18F-FDG-PET/CT is a useful tool in differ-
entiating benign from malignant lesions, it cannot be
used for specifically determining malignant lesions.
Some infectious or inflammatory lesions can also cause
high 18F-FDG uptake [20]. For example, Chen et al. [21] re-
ported a patient with an adnexal mass referred for 18F-FDG-
PET/CT scan owing to elevated tumor marker levels.
The 18F-FDG-PET/CT scan showed multiple hyper-
metabolic foci in the peritoneum that mimicked periton-
eal carcinomatosis. However, peritoneal tuberculosis was
confirmed later. In our study, 3 out of 7 benign lesions
were due to pelvic tuberculosis and mimicked peritoneal
carcinomatosis. Conversely, most advanced stage ovarian
cancers show peritoneal metastasis, and such peritoneal
lesions often cause confusion during diagnosis because
images obtained for these cancers are similar to those ob-
tained for benign inflammatory conditions involving the
gross peritoneal surface, as seen in our series.
Generally, whole-body 18F-FDG-PET/CT examination
is performed 1 h after the administration of 18F-FDG.
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of the radiotracer, which is 110 min [17]. However, many
different acquisition protocols have been proposed to
overcome the aforementioned false-negative or false-
positive results obtained with 18F-FDG-PET/CT. Saito
et al. [15] used a protocol involving early-phase and
delayed-phase scans (1 h and 2 h after 18F-FDG adminis-
tration) in 48 consecutive patients with intraductal papil-
lary mucinous neoplasia of the pancreas. In this study,
SUVmax increased further in the delayed phase imaging
in 92.3% patients with malignant pancreatic neoplasia,
and only 60.0% of those with benign pancreatic neopla-
sia. This result is consistent with that of ours, in which
SUVmax increased significantly in delayed phase PET/CT
in malignant but not benign lesions. Cheng et al. per-
formed dual-phase 18F-FDG-PET/CT in 35 patients with
equivocal infiltrative hepatic lesions on abdominal CT or
MRI scans [16]. In contrast to our study, the authors ob-
served that SUVmax was significantly higher in infiltra-
tive hepatic malignancies than in benign lesions in both
early (5.9 ± 5.0 versus 3.9 ± 1.7, respectively) and delayed
images (6.8 ± 10.2 versus 4.1 ± 3.9, respectively). Thus,
early phase SUVmax of benign and malignant lesions
were significantly different. In our study, only the AUC
of SUVmax2 was statistically significant in differentiating
benign from malignant lesions. This might be attributed
to either a different time point (45 min) for the early
phase 18F-FDG-PET/CT examination or organ-specific
characteristics. Caprio et al. evaluated the performance
of dual-phase 18F-FDG-PET/CT in 48 patients suspected
with breast lesions [17]. In their study, dual-time point
acquisition of 18F-FDG-PET/CT displayed an accuracy
of 85% for lesions with a SUVmax ≥ 2.5, with sensitivity
and specificity values of 81% and 100% compared with
63% and 100%, respectively, for the single-time point ac-
quisition. In our study, the sensitivity and specificity of
the SUVmax2 were 100% and 57.1%, respectively, with a
SUVmax2 > 3.9. The relatively small number of patients
and the different time point of the (3 h) in delayed phase
18F-FDG-PET/CT examination might account for the
differences in sensitivity and specificity. Yang et al. inves-
tigated whether adding delayed phase imaging can im-
prove diagnostic ability of 18F-FDG-PET in evaluating
solitary pulmonary nodules [18]. In their study, com-
bined early and delayed phase scans of 28 patients
showed correct diagnosis of the 3 malignant lesions with
an initial SUV < 2.5. Despite minor differences in the
study design and results compared to those of our study,
the abovementioned studies confirmed the clinical use-
fulness of dual-phase PET/CT in differentiating benign
from malignant lesions.
The major limitations of the current study include the
small number of patients. Although patients were pro-
spectively enrolled at the beginning of this study,selection bias could have been introduced. In other
words, the clinicians’ attitudes to dual-phase PET/CT
might affect the referral of patients. Second, this study
was performed in a single institution. Differences in
image acquisition and interpretation might influence the
study results. Therefore, an additional large-scale, pro-
spective study is necessary to check if our findings have
an impact on future clinical practice. In addition, cost-
effectiveness analysis should also be conducted. Despite
these limitations, the findings of the present study pro-
vide useful information for the management of patients
with equivocal adnexal masses; the sensitivities of both
MRI and single-phase 18F-FDG-PET/CT for detecting
ovarian cancer have reported to be similar [22,23].
Hence, if differential diagnosis of an adnexal mass is in-
determinate by MRI, then probably the usefulness of
single-phase 18F-FDG-PET/CT are also limited. Dual-
phase 18F-FDG-PET/CT may be a better procedure in
resolving this ambiguity. Accurate preoperative assess-
ment could help clinicians perform prompt debulking
surgery in patients with “true positive” ovarian cancers,
and avoid unnecessary surgery in patients with benign
conditions.
Conclusion
SUVmax2 obtained from dual-phase
18F-FDG-PET/CT is
a useful parameter in differentiating benign from malig-
nant lesions in patients with indeterminate adnexal
masses. Further studies with larger patient populations
are warranted.
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